Exploring lesser-known proteins that could be targeted for cancer treatment
Illuminating understudied druggable proteins using pan-cancer proteogenomics data
['FUNDING_U01'] · BAYLOR COLLEGE OF MEDICINE · NIH-10671574
This study is looking at some lesser-known proteins that might be important in cancer and how we can use existing medicines to target them, with the hope of finding new treatment options for patients.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BAYLOR COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10671574 on ClinicalTrials.gov |
What this research studies
This research investigates proteins that are often overlooked but may play a significant role in cancer development and treatment. By analyzing large datasets from various cancer types, the project aims to uncover new insights about these proteins and how they can be targeted with existing drugs. The approach utilizes advanced data analysis techniques to generate hypotheses about the functions of these proteins and their potential as therapeutic targets. Patients may benefit from new treatment options that arise from a better understanding of these 'dark' proteins.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with various types of cancer who may benefit from novel therapeutic approaches.
Not a fit: Patients with non-malignant conditions or those whose cancers are already well understood may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new cancer therapies targeting previously understudied proteins.
How similar studies have performed: Previous research utilizing similar proteogenomics approaches has shown promise in identifying new therapeutic targets in cancer treatment.
Where this research is happening
HOUSTON, UNITED STATES
- BAYLOR COLLEGE OF MEDICINE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHANG, BING — BAYLOR COLLEGE OF MEDICINE
- Study coordinator: ZHANG, BING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer